Compare LNSR & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNSR | CDXS |
|---|---|---|
| Founded | 2004 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.7M | 141.8M |
| IPO Year | 2005 | 2008 |
| Metric | LNSR | CDXS |
|---|---|---|
| Price | $11.80 | $1.12 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 39.8K | ★ 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.54 |
| EPS | N/A | ★ N/A |
| Revenue | $53,494,000.00 | ★ $138,590,000.00 |
| Revenue This Year | $19.55 | $15.64 |
| Revenue Next Year | $35.89 | $5.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 26.87 | ★ 32.30 |
| 52 Week Low | $9.18 | $1.05 |
| 52 Week High | $17.31 | $4.30 |
| Indicator | LNSR | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 33.75 |
| Support Level | N/A | N/A |
| Resistance Level | N/A | $2.56 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 16.18 |
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.